Anavex Life Sciences Corp (AVXL)

[falconer66a]

AVXL. Now, or later?

OR Anavex fails to get consistent efficacy results from the trials.

If this is a reasonable possibility, why should anyone take or hold an AVXL position?

Of course, for many of us, with a sound understanding of the unique mechanisms of action (MOAs) of blarcamesine, we will confidently hold our Anavex positions.

For us, the controlling facts are these. First, there are profound and detailed outcomes of blarcamesine in trans-genic murines, lab rodents that have had human CNS-disease genes inserted and have the same symptoms as humans with those diseases. Blarcamesine, without side effects of any consequence, have successfully treated those little rodents.

Pretty encouraging. But, as so often contended by Anavex naysayers, mice are not men; murine studies very commonly fail when moved to clinical trials in real humans. Has this been the record with blarcamesine?

Quite not. Hundreds of diseased humans have taken blarcamesine in early-phase clinical trials. Clinical results for them have paralleled the results in murines; also without disqualifying adverse events, side effects. In a few cases, some headaches or dizziness, which didn’t progress; prompt resolution. Nothing else.

Blarcamesine is not in any way teratogenic, creating birth defects. It does not change or disrupt genes or nucleotide sequences in DNA. It is not carcinogenic. It has no debilitating effects on the immune system. It does not negatively affect endocrine functions (hormones). It creates no psychiatric problems. No induced cardiovascular problems. It has never demonstrated, in murines or humans, any of the common but severe side effects of drugs acting strongly in the central nervous system.

All of that makes sense, after examining and understanding how blarcamesine works, by uniquely activating the sigma-1 receptor protein. Only good things happen when that happens.

Those who wish to retain a “But let’s wait until phase 3 clinical results prove all of this.” perspective, well and good. Wait to take an AVXL position then.

But, personally, I’ve scrutinized the biological data for blarcamesine, and strongly believe, as proven so far to date, final clinical results will be positive; that the FDA will then be compelled to approve blarcamesine. Differing AVXL investment strategies. Each to his own.